Small Cajal body-specific RNA 9 (SCARNA9)

Small Cajal body-specific RNA 9 (SCARNA9) is a member of the scaRNA family, a class of small non-coding RNAs localized to Cajal bodies within the nucleus[3][1][5]. These RNAs serve as guide RNAs for the site-specific modification of spliceosomal snRNAs, particularly U2, by directing enzymes responsible for pseudouridylation and 2'-O-methylation. SCARNA9 is processed by the Drosha-DGCR8 microprocessor complex, resulting in fragments such as mgU2-19 and mgU2-30, which contribute to snRNA maturation[2]. As lncC11orf54-1, SCARNA9 has been implicated in neuroinflammatory response via activation of NF-kappaB signaling[4]. SCARNA9 is not considered a classical drug target like a receptor or enzyme, and no drugs are known to interact with it. It belongs to the molecular family of small non-coding RNAs that orchestrate RNA modification, essential for spliceosome function and proper cell regulation. Currently, there are no direct disease biomarker or safety concerns associated with SCARNA9.

Other names

mgU2-19/30Z32lncC11orf54-1mgU2-19/30 scaRNASmall Cajal body-specific RNA 9SCARNA9

Not applicable for drugs, but mechanistically, SCARNA9 acts by guiding enzymes to sites of pseudouridylation and 2'-O-methylation on spliceosomal snRNAs through base-pairing interactions